Payment overview · 2025
General Payments
$404.58
16 reported records · 6 companies
Healthcare provider profile · identity verified
Jaykumar H Shah, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1376514661
Verified facts
What the public records show
CMS Open Payments records show Jaykumar H Shah, M.D. received $404.58 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.86 | 44.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.34 | 21.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.78 | 13.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.21 | 8.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.55 | 6.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.84 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $404.58 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $179.86 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.34 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $80.33 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.66 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 100 |
| Metformin Hcl | Metformin Hcl | 275 | 85 |
| Simvastatin | Simvastatin | 271 | 72 |
| Lisinopril | Lisinopril | 265 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 72 |
| Gabapentin | Gabapentin | 252 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 63 |
| Furosemide | Furosemide | 215 | 57 |
| Omeprazole | Omeprazole | 186 | 40 |
| Alprazolam | Alprazolam | 185 | 35 |
| Losartan Potassium | Losartan Potassium | 178 | 49 |
| Potassium Chloride | Potassium Chloride | 167 | 42 |
| Azithromycin | Azithromycin | 157 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 27 |
| Donepezil Hcl | Donepezil Hcl | 141 | 23 |
| Finasteride | Finasteride | 136 | 31 |
| Glipizide | Glipizide | 134 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 49 |
| Famotidine | Famotidine | 119 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 32 |
| Lorazepam | Lorazepam | 118 | 30 |
| Atenolol | Atenolol | 107 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Sertraline Hcl | Sertraline Hcl | 103 | 20 |
| Carvedilol | Carvedilol | 100 | 30 |
| Jardiance | Empagliflozin | 100 | 18 |
| Trazodone Hcl | Trazodone Hcl | 99 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 17 |
| Irbesartan | Irbesartan | 95 | 23 |
| Valsartan | Valsartan | 95 | 27 |
| Eliquis | Apixaban | 88 | 21 |
| Baclofen | Baclofen | 85 | 31 |
| Tramadol Hcl | Tramadol Hcl | 83 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 55 |
| Meloxicam | Meloxicam | 77 | 16 |
| Allopurinol | Allopurinol | 75 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 22 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 20 |
| Alendronate Sodium | Alendronate Sodium | 64 | 18 |
| Levetiracetam | Levetiracetam | 64 | suppressed |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Amoxicillin | Amoxicillin | 61 | 48 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 61 | 14 |
| Lovastatin | Lovastatin | 60 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Terazosin Hcl | Terazosin Hcl | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 22 |
| Ozempic | Semaglutide | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Cephalexin | Cephalexin | 45 | 35 |
| Mirtazapine | Mirtazapine | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Prednisone | Prednisone | 40 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Spironolactone | Spironolactone | 34 | 11 |
| Temazepam | Temazepam | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 16 |
| Montelukast Sodium | Montelukast Sodium | 32 | 12 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Lactulose | Lactulose | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $404.58 · 16 records | AstraZeneca Pharmaceuticals LP | Auvelity, BREZTRI, CAPVAXIVE, GARDASIL 9, JARDIANCE, OTEZLA, REPATHA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error